McIlrath & Eck’s DexCom DXCM Stock Holding History

McIlrath & Eck’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-80	Closed	-$6.22K	–	954
2024 Q4	$6.22K	Hold	80	–	–	﹤0.01%	713
2024 Q3	$5.36K	Hold	80	–	–	﹤0.01%	735
2024 Q2	$9.07K	Hold	80	–	–	﹤0.01%	622
2024 Q1	$11.1K	Hold	80	–	–	﹤0.01%	581
2023 Q4	$9.93K	Hold	80	–	–	﹤0.01%	560
2023 Q3	$7.46K	Hold	80	–	–	﹤0.01%	586
2023 Q2	$10.3K	Sell	80 -6	-7%	-$726	﹤0.01%	556
2023 Q1	$9.99K	Buy	86 +6	+8%	+$672	﹤0.01%	554
2022 Q4	$9.06K	Hold	80	–	–	﹤0.01%	553
2022 Q3	$6K	Hold	80	–	–	﹤0.01%	604
2022 Q2	$6K	Hold	80	–	–	﹤0.01%	586
2022 Q1	$10K	Hold	80	–	–	﹤0.01%	523
2021 Q4	$11K	Hold	80	–	–	﹤0.01%	522
2021 Q3	$11K	Hold	80	–	–	﹤0.01%	506
2021 Q2	$9K	Hold	80	–	–	﹤0.01%	530
2021 Q1	$7K	Hold	80	–	–	﹤0.01%	531
2020 Q4	$7K	Hold	80	–	–	﹤0.01%	476
2020 Q3	$8K	Buy	+80	New	+$8.36K	﹤0.01%	417

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

McIlrath & Eck's DXCM Position: Q1 2025 in Review

McIlrath & Eck sold out of DexCom (DXCM) in Q1 2025, closing a stake of 80 shares — an estimated $6.22K sold.

McIlrath & Eck first reported a position in DXCM in Q3 2020 and held it in 18 quarters. The position peaked at $11.1K in Q1 2024. 932 funds tracked by Wall St. Rank hold DXCM as of Q1 2025.

McIlrath & Eck reported no remaining DexCom position as of Q1 2025 after selling out during the quarter.
McIlrath & Eck sold 80 DexCom shares in Q1 2025, an estimated $6.22K.
McIlrath & Eck first reported a position in DexCom in Q3 2020 and held it in 18 quarters.
McIlrath & Eck's DexCom position peaked at $11.1K in Q1 2024.
932 funds tracked by Wall St. Rank held DexCom as of Q1 2025.

Based on McIlrath & Eck's 13F filing for Q1 2025, filed 16 May 2025.